Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN stock opened at $0.19 on Friday. The stock has a fifty day moving average price of $0.27 and a 200 day moving average price of $0.32. The stock has a market cap of $4.02 million, a PE ratio of -0.03 and a beta of 0.87. Oragenics has a 1 year low of $0.18 and a 1 year high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.